Search research articles
Contact Us
Filters
Showing results (31-40 of 65) with videos related to
Page
of 7
Sort By:
Clinical Cardiology
|
February 1, 2014
Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome
June-Wha Rhee, Stephen D Wiviott, Benjamin M Scirica, et al.
Journal of the American Heart Association
|
May 3, 2014
The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome
Amy Sarma, Christopher P Cannon, James de Lemos, et al.
Journal of the American College of Cardiology
|
March 19, 2013
Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51)
Jessica L Mega, Eugene Braunwald, Sabina A Murphy, et al.
JACC. Cardiovascular Interventions
|
November 19, 2013
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38)
Oluseyi Ojeifo, Stephen D Wiviott, Elliott M Antman, et al.
Journal of the American College of Cardiology
|
July 21, 2004
B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy
Jessica L Mega, David A Morrow, James A De Lemos, et al.
Plos One
|
June 17, 2014
Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism
Aslan T Turer, Gregory D Lewis, John F O'Sullivan, et al.
American Heart Journal
|
May 17, 2005
Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial
Jessica L Mega, David A Morrow, Marc S Sabatine, et al.
Thrombosis and Haemostasis
|
March 25, 2016
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial
Edward T Carreras, Willibald Hochholzer, Andrew L Frelinger, et al.
Circulation
|
February 26, 2015
Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association
Jeffrey B Washam, Charles A Herzog, Amber L Beitelshees, et al.
The New England Journal of Medicine
|
December 25, 2008
Cytochrome p-450 polymorphisms and response to clopidogrel
Jessica L Mega, Sandra L Close, Stephen D Wiviott, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 65) with videos related to
Sort By:
Page
of 7
Clinical Cardiology
|
February 1, 2014
Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome
June-Wha Rhee, Stephen D Wiviott, Benjamin M Scirica, et al.
Journal of the American Heart Association
|
May 3, 2014
The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome
Amy Sarma, Christopher P Cannon, James de Lemos, et al.
Journal of the American College of Cardiology
|
March 19, 2013
Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51)
Jessica L Mega, Eugene Braunwald, Sabina A Murphy, et al.
JACC. Cardiovascular Interventions
|
November 19, 2013
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38)
Oluseyi Ojeifo, Stephen D Wiviott, Elliott M Antman, et al.
Journal of the American College of Cardiology
|
July 21, 2004
B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy
Jessica L Mega, David A Morrow, James A De Lemos, et al.
Plos One
|
June 17, 2014
Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism
Aslan T Turer, Gregory D Lewis, John F O'Sullivan, et al.
American Heart Journal
|
May 17, 2005
Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial
Jessica L Mega, David A Morrow, Marc S Sabatine, et al.
Thrombosis and Haemostasis
|
March 25, 2016
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial
Edward T Carreras, Willibald Hochholzer, Andrew L Frelinger, et al.
Circulation
|
February 26, 2015
Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association
Jeffrey B Washam, Charles A Herzog, Amber L Beitelshees, et al.
The New England Journal of Medicine
|
December 25, 2008
Cytochrome p-450 polymorphisms and response to clopidogrel
Jessica L Mega, Sandra L Close, Stephen D Wiviott, et al.
Page
of 7